Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Erik Berk

Showing results (11-20 of 19) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 19 results.
The Journal of Pharmacology and Experimental Therapeutics|March 1, 2006
Endothelial targeting of high-affinity multivalent polymer nanocarriers directed to intercellular adhesion molecule 1Silvia Muro, Thomas Dziubla, Weining Qiu, et al.
Frontiers in Immunology|June 18, 2015
Rationale for a Multimodality Strategy to Enhance the Efficacy of Dendritic Cell-Based Cancer ImmunotherapyJashodeep Datta, Erik Berk, Jessica A Cintolo, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 19, 2009
Independent regulation of chemokine responsiveness and cytolytic function versus CD8+ T cell expansion by dendritic cellsPayal B Watchmaker, Erik Berk, Ravikumar Muthuswamy, et al.
Immunity|June 20, 2006
The Noxa/Mcl-1 axis regulates susceptibility to apoptosis under glucose limitation in dividing T cellsNuno L Alves, Ingrid A M Derks, Erik Berk, et al.
JAMA Oncology|January 1, 2016
Association of Depressed Anti-HER2 T-Helper Type 1 Response With Recurrence in Patients With Completely Treated HER2-Positive Breast Cancer: Role for Immune MonitoringJashodeep Datta, Megan Fracol, Matthew T McMillan, et al.
Journal of Immunology (Baltimore, Md. : 1950)|March 7, 2008
Memory CD8+ T cells protect dendritic cells from CTL killingPayal B Watchmaker, Julie A Urban, Erik Berk, et al.
Cancer Research|May 18, 2012
NF-κB hyperactivation in tumor tissues allows tumor-selective reprogramming of the chemokine microenvironment to enhance the recruitment of cytolytic T effector cellsRavikumar Muthuswamy, Erik Berk, Beth Fallert Junecko, et al.
Breast Cancer Research : BCR|May 23, 2015
Anti-HER2 CD4(+) T-helper type 1 response is a novel immune correlate to pathologic response following neoadjuvant therapy in HER2-positive breast cancerJashodeep Datta, Erik Berk, Shuwen Xu, et al.
Oncoimmunology|October 10, 2015
Progressive loss of anti-HER2 CD4<sup>+</sup> T-helper type 1 response in breast tumorigenesis and the potential for immune restorationJashodeep Datta, Cinthia Rosemblit, Erik Berk, et al.
Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
The Journal of Pharmacology and Experimental Therapeutics|March 1, 2006
Endothelial targeting of high-affinity multivalent polymer nanocarriers directed to intercellular adhesion molecule 1Silvia Muro, Thomas Dziubla, Weining Qiu, et al.
Frontiers in Immunology|June 18, 2015
Rationale for a Multimodality Strategy to Enhance the Efficacy of Dendritic Cell-Based Cancer ImmunotherapyJashodeep Datta, Erik Berk, Jessica A Cintolo, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 19, 2009
Independent regulation of chemokine responsiveness and cytolytic function versus CD8+ T cell expansion by dendritic cellsPayal B Watchmaker, Erik Berk, Ravikumar Muthuswamy, et al.
Immunity|June 20, 2006
The Noxa/Mcl-1 axis regulates susceptibility to apoptosis under glucose limitation in dividing T cellsNuno L Alves, Ingrid A M Derks, Erik Berk, et al.
JAMA Oncology|January 1, 2016
Association of Depressed Anti-HER2 T-Helper Type 1 Response With Recurrence in Patients With Completely Treated HER2-Positive Breast Cancer: Role for Immune MonitoringJashodeep Datta, Megan Fracol, Matthew T McMillan, et al.
Journal of Immunology (Baltimore, Md. : 1950)|March 7, 2008
Memory CD8+ T cells protect dendritic cells from CTL killingPayal B Watchmaker, Julie A Urban, Erik Berk, et al.
Cancer Research|May 18, 2012
NF-κB hyperactivation in tumor tissues allows tumor-selective reprogramming of the chemokine microenvironment to enhance the recruitment of cytolytic T effector cellsRavikumar Muthuswamy, Erik Berk, Beth Fallert Junecko, et al.
Breast Cancer Research : BCR|May 23, 2015
Anti-HER2 CD4(+) T-helper type 1 response is a novel immune correlate to pathologic response following neoadjuvant therapy in HER2-positive breast cancerJashodeep Datta, Erik Berk, Shuwen Xu, et al.
Oncoimmunology|October 10, 2015
Progressive loss of anti-HER2 CD4<sup>+</sup> T-helper type 1 response in breast tumorigenesis and the potential for immune restorationJashodeep Datta, Cinthia Rosemblit, Erik Berk, et al.
Pageof 2